Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials

International Journal of Cardiology

Volumn 228, Issue , 2017, Pages 352-358

  Saad, Marwan ^a   Mahmoud, Ahmed N ^b   Elgendy, Islam Y ^b   Abuzaid, Ahmed ^c   Barakat, Amr F ^d   Elgendy, Akram Y ^b   Al Ani, Mohammad ^b   Mentias, Amgad ^e   Nairooz, Ramez ^a   Bavry, Anthony A ^b   Mukherjee, Debabrata ^f  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c University of Medicine and Dentistry of New Jersey   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular outcomes; Diabetes mellitus; Meta analysis; Mortality; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PLACEBO; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; CARDIOVASCULAR MORTALITY; CAUSAL ATTRIBUTION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; AGE; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; PROGNOSIS; SEX DIFFERENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGE FACTORS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEX FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84995814726     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.181     Document Type: Article

References (40)

1. [1] Syed, S.H., Gosavi, S., Shami, W., Bustamante, M., Farah, Z., Teleb, M., Abbas, A., Said, S., Mukherjee, D., A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc. Hematol. Agents Med. Chem. 13:2 (2015), 105–112.
2. [2] Bakris, G.L., Fonseca, V.A., Sharma, K., Wright, E.M., Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 75:12 (2009), 1272–1277.
3. [3] Chao, E.C., Henry, R.R., SGLT2 inhibition—a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 9:7 (2010), 551–559.
4. [4] Bailey, C.J., Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol. Sci. 32:2 (2011), 63–71.
5. [5] Voelker, R., Update on SGLT2 inhibitor warning. JAMA, 315(3), 2016, 243.
6. [6] Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U.C., Woerle, H.J., Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 17:10 (2015), 936–948.
7. [7] Bailey, C.J., Gross, J.L., Hennicken, D., Iqbal, N., Mansfield, T.A., List, J.F., Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med., 11, 2013, 43.
8. [8] Wilding, J.P.H., Charpentier, G., Hollander, P., González-Gálvez, G., Mathieu, C., Vercruysse, F., Usiskin, K., Law, G., Black, S., Canovatchel, W., Meininger, G., Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int. J. Clin. Pract. 67:12 (2013), 1267–1282.
9. [9] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373:22 (2015), 2117–2128.
10. [10] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
11. [11] Liu, X.-Y., Zhang, N., Chen, R., Zhao, J.-G., Yu, P., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J. Diabetes Complicat. 29:8 (2015), 1295–1303.
12. [12] Yang, T., Lu, M., Ma, L., Zhou, Y., Cui, Y., Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. Eur. J. Clin. Pharmacol. 71:11 (2015), 1325–1332.
13. [13] Sun, Y.-N., Zhou, Y., Chen, X., Che, W.-S., Leung, S.-W., The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open, 4(4), 2014, e004619.
14. [14] Berhan, A., Barker, A., Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr. Disord., 13, 2013, 58.
15. [15] Monami, M., Nardini, C., Mannucci, E., Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 16:5 (2014), 457–466.
16. [16] Wu, J.H.Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., Neal, B., Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 4:5 (2016), 411–419.
17. [17] Jüni, P., Altman, D.G., Egger, M., Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:7303 (2001), 42–46.
18. [18] O'Connor, D., Green, S., Higgins, J.P., 9.4.4.2. Peto odds ratio method. Higgins, J.P., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions, 2011, The Cochrane Collaboration.
19. [19] Higgins, J.P.T., Green, S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. 2011, The Cochrane Collaboration (Available from www.cochrane-handbook.org).
20. [20] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7:3 (1986), 177–188.
21. [21] Higgins, J.P.T., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
22. [22] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315:7109 (1997), 629–634.
23. [23] Effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content. Available at https://clinicaltrials.gov/ct2/show/NCT02383238. Last accessed 2016.
24. [24] Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur. Heart J. 37:19 (2016), 1526–1534.
25. [25] Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U.C., Woerle, H.J., Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38:3 (2015), 420–428.
26. [26] McMurray, J., EMPA-REG - the “diuretic hypothesis”. J. Diabetes Complicat. 30:1 (2015), 3–4.
27. [27] Kovacs, C.S., Seshiah, V., Merker, L., Christiansen, A.V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H.-J., Broedl, U.C., Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin. Ther. 37:8 (2015), 1773–1788.e1.
28. [28] Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., Broedl, U.C., Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37:7 (2014), 1815–1823.
29. [29] Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., Johansen, O.E., Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab. 17:12 (2015), 1180–1193.
30. [30] Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O.E., Woerle, H.-J., von Eynatten, M., Broedl, U.C., The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc. Diabetol., 13, 2014, 28.
31. [31] Cardoso, C.R.L., Ferreira, M.T., Leite, N.C., Salles, G.F., Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study. Diabetes Care 36:11 (2013), 3772–3778.
32. [32] Ronco, C., McCullough, P., Anker, S.D., Anand, I., Aspromonte, N., Bagshaw, S.M., Bellomo, R., Berl, T., Bobek, I., Cruz, D.N., Daliento, L., Davenport, A., Haapio, M., Hillege, H., House, A.A., Katz, N., Maisel, A., Mankad, S., Zanco, P., Mebazaa, A., Palazzuoli, A., Ronco, F., Shaw, A., Sheinfeld, G., Soni, S., Vescovo, G., Zamperetti, N., Ponikowski, P., Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 31:6 (2010), 703–711.
33. [33] Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O.E., Woerle, H.J., Broedl, U.C., Zinman, B., EMPA-REG OUTCOME investigators. empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375:4 (2016), 323–334.
34. [34] Barakat, A.F., Saad, M., Abuzaid, A., Mentias, A., Mahmoud, A., Elgendy, I.Y., Perioperative statin therapy for patients undergoing coronary artery bypass grafting. Ann. Thorac. Surg. 101:2 (2016), 818–825.
35. [35] Elgendy, I.Y., Mahmoud, A., Huo, T., Beaver, T.M., Bavry, A., A. Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting. Am. J. Cardiol. 115:11 (2015), 1523–1528.
36. [36] Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K.W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., Jiang, J., Vercruysse, F., Meininger, G., Matthews, D., Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 38:3 (2015), 403–411.
37. [37] FDA Drug Safety Communication: interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate. Available at http://www.fda.gov/Drugs/DrugSafety/ucm500965.htm (Accessed July 16, 2016).
38. [38] Safety alerts for human medical products - canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR): drug safety communication - strengthened kidney warnings. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm. Accessed July 16, 2016.
39. [39] Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events. Available at https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed July 20, 2016.
40. [40] Safety and effectiveness of SGLT-2 inhibitors in patients with heart failure and diabetes. Available at https://clinicaltrials.gov/ct2/show/NCT02397421. Accessed July 20, 2016.